Skip to main content

Table 1 Associations between sample characteristics and use of varenicline or NRT Rx

From: Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the “real world”

Variable Varenicline NRT Rx P
(N = 118) (N = 152)
Non-smoker at follow-up 39.8 (47) 19.7 (30) <0.001
Age at baseline, mean (SD) 46.0 (12.2) 51.7 (13.8) <0.001
Female sex 57.6 (68) 56.6 (86) 0.863
Social grade    
   AB 2.5 (3) 10.5 (16) <0.001
   C1 29.7 (35) 17.8 (27)
   C2 23.7 (28) 11.8 (18)
   D 22.0 (26) 18.4 (28)
   E 22.0 (26) 41.4 (63)
Number of quit attempts prior to the most recent one at follow-up    
   0 83.1 (98) 73.0 (111) 0.147
   1 12.7 (15) 19.7 (30)
   2 4.2 (5) 7.2 (11)
Time since last quit attempt started at follow-up    
   <=1 week 7.6 (9) 9.2 (14) 0.097
   1–4 weeks 8.5 (10) 13.8 (21)
   4–8 weeks 22.0 (26) 18.4 (28)
   8–12 weeks 22.0 (26) 31.6 (48)
   12–26 weeks 39.8 (47) 27.0 (41)
Stopped abruptly during last quit attempt at follow-up (versus cut down first) 35.6 (42) 52.0 (79) 0.007
Time spent with urges to smoke at baseline, mean (SD) 3.6 (1.3) 3.2 (1.1) 0.006
Strength of urges to smoke at baseline, mean (SD) 2.4 (1.1) 2.3 (1.0) 0.481
  1. Figures are presented as percentage within varenicline/NRT Rx (N), unless stated otherwise. Time spent with urges to smoke: 1 (not at all) to 6 (all the time). Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges). NRT Rx = nicotine replacement therapy on prescription. Social grade: AB = managerial and professional occupations, C1 = intermediate occupations, C2 = small employers and own account workers, D = lower supervisory and technical occupations, and E = semi-routine and routine occupations, never workers, and long-term unemployed.